144 related articles for article (PubMed ID: 36149166)
21. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
22. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors.
Yabe M; Miranda RN; Medeiros LJ
Hum Pathol; 2018 Apr; 74():5-16. PubMed ID: 29337025
[TBL] [Abstract][Full Text] [Related]
23. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin.
Cooke CB; Krenacs L; Stetler-Stevenson M; Greiner TC; Raffeld M; Kingma DW; Abruzzo L; Frantz C; Kaviani M; Jaffe ES
Blood; 1996 Dec; 88(11):4265-74. PubMed ID: 8943863
[TBL] [Abstract][Full Text] [Related]
24. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Shah ED; Coburn ES; Nayyar A; Lee KJ; Koliani-Pace JL; Siegel CA
Aliment Pharmacol Ther; 2020 Mar; 51(5):527-533. PubMed ID: 31990422
[TBL] [Abstract][Full Text] [Related]
25. A rare case of hepatosplenic γδ T-cell lymphoma expressing CD19 with ring chromosome 7 and trisomy 8.
Jain H; Shetty D; Jain H; Sengar M; Khattry N; Subramanian PG
Cancer Genet; 2018 Dec; 228-229():17-20. PubMed ID: 30553467
[TBL] [Abstract][Full Text] [Related]
26. Hepatosplenic T-cell lymphoma presented with massive splenomegaly and pancytopenia - a case report.
Sukrisman L; Rajabto W; Harahap AS; Fanggidae ESDE; Ham MF; Priantono D
Klin Onkol; 2023; 36(3):246-250. PubMed ID: 37353354
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotyping of mature T/NK cell neoplasm presenting as leukemia.
Gujral S; Polampalli S; Badrinath Y; Kumar A; Subramanian PG; Nair R; Sengar M; Nair C
Indian J Cancer; 2010; 47(2):189-93. PubMed ID: 20448385
[TBL] [Abstract][Full Text] [Related]
28. [Primary hepatosplenic (gamma delta) T-cell lymphoma: clinico-pathologic analysis of 3 cases].
Plank L; Fricová M; Stecová N; Tóthová E; Mudronová B; Fuschsberger P; Mociková K; Genserková H; Kreze O; Mociková H
Vnitr Lek; 1998 Sep; 44(9):528-34. PubMed ID: 10358463
[TBL] [Abstract][Full Text] [Related]
29. Development of hepatosplenic gammadelta T-cell lymphoma with pancytopenia during early pregnancy: a case report and review of the literature.
Niitsu N; Kohri M; Togano T; Nakamine H; Nakamura S; Iwabuchi K; Higashihara M
Eur J Haematol; 2004 Nov; 73(5):367-71. PubMed ID: 15458516
[TBL] [Abstract][Full Text] [Related]
30. Hepatosplenic T-cell lymphoma in a young immunocompetent man.
Petrova M; Gomes MM; Carda JP; Pereira de Moura J
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 27033291
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
32. Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Review With an Emphasis on Diagnostic Differentiation From Other T-Cell/Natural Killer-Cell Neoplasms.
Shi Y; Wang E
Arch Pathol Lab Med; 2015 Sep; 139(9):1173-80. PubMed ID: 26317456
[TBL] [Abstract][Full Text] [Related]
33. De novo CD3 negative hepatosplenic T-cell lymphoma: diagnostic challenges and pitfalls.
Kapur LH; Khaled Y; Solh M; Ward D; Chang CC
Arch Pathol Lab Med; 2014 Jul; 138(7):969-73. PubMed ID: 24978925
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic and molecular characterization of a hepatosplenic T-cell lymphoma: report of a novel chromosomal aberration.
Mandava S; Sonar R; Ahmad F; Yadav AK; Chheda P; Ramani M; Gupta AD; Das BR
Cancer Genet; 2011 Feb; 204(2):103-7. PubMed ID: 21504708
[TBL] [Abstract][Full Text] [Related]
35. Hepatosplenic gammadelta T cell lymphoma: a diagnostic pitfall.
Veldt BJ; Meijers C; Zondervan PE; de Man RA
J Hepatol; 2003 Sep; 39(3):455-7. PubMed ID: 12927937
[No Abstract] [Full Text] [Related]
36. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?
Subramaniam K; Yeung D; Grimpen F; Joseph J; Fay K; Buckland M; Talaulikar D; Elijah J; Clarke AC; Pavli P; Moore J
Intern Med J; 2014 Mar; 44(3):287-90. PubMed ID: 24621284
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience.
Bojanini L; Jiang L; Tun AJ; Ayala E; Menke DM; Hoppe B; Kharfan-Dabaja MA; Tun HW; Alhaj Moustafa M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):106-112.e1. PubMed ID: 33160933
[TBL] [Abstract][Full Text] [Related]
38. Hepatosplenic gamma delta T-cell lymphoma. A distinctive aggressive lymphoma type.
Wong KF; Chan JK; Matutes E; McCarthy K; Ng CS; Chan CH; Ma SK
Am J Surg Pathol; 1995 Jun; 19(6):718-26. PubMed ID: 7755158
[TBL] [Abstract][Full Text] [Related]
39. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas.
Macon WR; Levy NB; Kurtin PJ; Salhany KE; Elkhalifa MY; Casey TT; Craig FE; Vnencak-Jones CL; Gulley ML; Park JP; Cousar JB
Am J Surg Pathol; 2001 Mar; 25(3):285-96. PubMed ID: 11224598
[TBL] [Abstract][Full Text] [Related]
40. Hepatosplenic gamma delta T-cell lymphoma with a novel cytogenetic alteration and cerebrospinal fluid infiltration: biological and clinical features.
Ferrari D; Girmenia G; Migliorini L; Nosari A; Morra E
Haematologica; 2002 Mar; 87(3):ECR11. PubMed ID: 11869957
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
